Vancouver, British Columbia--(Newsfile Corp. - July 13, 2016) - Chris Schaber, President & CEO of Soligenix Inc (OTCQB: SNGX), shares of this company is focused on developing therapies for rare diseases.
If you cannot view the video above, please visit:
Soligenix Inc. is being featured on CBC's Documentary Channel, Jul 25 - Aug 7, 2016, Monday through Friday, throughout the day and evenings.
Soligenix Inc (OTC: SNGX)
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Their BioTherapeutics business segment is developing SGX301 as a first-in-class photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and their novel innate defense regulator technology dusquetide (SGX942) for the treatment of oral mucositis. http://www.soligenix.com/
About CEO Clips:
CEO Clips is the largest library of publicly traded company CEO videos in the US and Canada. These 90 second video profiles broadcast on national TV and are distributed online on top financial portals including: Thomson Reuters, BNN.ca, and Stockhouse.com. They are also disseminated via a video news release to several financial portals including Globe Investor, OTC Markets, TMX Money, and The National Post.
BTV - Business Television/CEO Clip Contact: Trina Schlingmann (604) 664-7401 x 5 email@example.com